+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

British Journal of Haematology 171(4): 530-538

The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P < 0·0001)]. IPS-3 outperformed the IPS-7 on risk prediction for both FFP and OS by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS-7 low risk patients were re-classified as intermediate risk and 13% of IPS-7 intermediate risk patients as low risk. For patients with advanced HL, the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057816897

Download citation: RISBibTeXText

PMID: 26343802

DOI: 10.1111/bjh.13634

Related references

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. Journal of Clinical Oncology 30(27): 3383-3388, 2012

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leukemia & Lymphoma 53(5): 812-819, 2012

Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. Chinese Medical Journal 129(23): 2780-2785, 2016

Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages. Leukemia & Lymphoma 57(8): 1839-1847, 2017

Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leukemia & Lymphoma 50(10): 1718-1720, 2010

Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma. Ai Zheng 25(8): 1013-1018, 2006

Tailored BEACOPP regimen for standard and high risk Hodgkin lymphoma based on early response to Ga67 scintigraphy and the international prognostic score for advanced Hodgkin disease. Blood 98(11 Part 2): 240b, November 16, 2001

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Annals of Oncology 13(12): 1908-1914, 2002

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Annals of Oncology 11(5): 617-623, 2000

Tailored BEACOPP Regimen for Unfavorable Hodgkin Lymphoma Based on Early Response to Ga67 /F18dg Scintigraphy and International Prognostic Score for Advanced Disease. Blood 100(11): Abstract No 3081, November 16, 2002

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine 339(21): 1506-1514, 1998

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leukemia & Lymphoma 49(11): 2091-2098, 2008

Usefulness of the prognostic score for advanced Hodgkin's disease in patients with human immunodeficiency virus-associated Hodgkin's lymphoma. Haematologica 85(3): 325-326, 2000

Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2018, 2018

Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatric Blood & Cancer (): -, 2016